Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant serplulimab + platinum doublet chemotherapy + SBRT for resectable or potentially resectable stage IB–IIIB small cell lung cancer
ChiCTR2600130978Phase 4Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of serplulimab in small cell lung cancer (SCLC), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: pathological complete response rate. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2600130978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130978.